Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors

Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICPi) have shown their superiority over conventional therapies to treat some cancers. ICPi are effective against immunogenic tumors. However, patients with tumors poorly infiltrated with immune cells do not respond to ICPi. Combining ICPi with other anticancer therapies...

Full description

Bibliographic Details
Main Authors: Magalie Dosset, Elodie Lauret-Marie Joseph, Thaiz Rivera Vargas, Lionel Apetoh
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cells
Subjects:
immunogenic therapy
immune checkpoint inhibitors
combined therapies
cancer
T cells
stem-cell like memory T cells
Online Access:https://www.mdpi.com/2073-4409/9/7/1727

Internet

https://www.mdpi.com/2073-4409/9/7/1727

Similar Items